Over the past month, shares of Dendreon (NASDAQ: DNDN) have risen 25%, amid talk that a buyout was a possibility. For now, that talk remains just talk; but the company has found a buyer for its New Jersey facility -- Novartis (NVS +0.96%) -- which will raise $43M for the company. In this video, Motley Fool health-care analyst David Williamson tells us why the sale was important for Dendreon, how Novartis will be putting its new facility to use, and if the rumor mill's buyout ideas may materialize somewhere down the road.
Dendreon Finds a Buyer
By Dave Williamson and Brenton Flynn – Dec 20, 2012 at 5:12PM
Dendreon makes a big sale.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid